May. 12 at 8:10 PM
$TLSI Q1 '26 Earnings Results & Recap
• Reported GAAP EPS of
$0.03 up 107.69% YoY
• Reported revenue of
$8.9M down -2.92% YoY
• TriSalus Life Sciences revised its 2026 revenue guidance to
$54M to
$57M, reflecting the impact of commercial expansion and the timing of FDA clearance for TriNav Advance.
